Clinical Trial Update: PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating XTR003 in combination with 18F-FDG PET imaging to assess myocardial viability in ischemic cardiomyopathy is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Cardiomyopathy

Drugs mentioned

• 18F-FDG (fluorodeoxyglucose F-18)
• XTR003 (XTR003)

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Ischemic Cardiomyopathy, Heart Failure | Phase 2 | Status: RECRUITING